Skip to main content
. 2024 Dec 1;30:37. doi: 10.1186/s40885-024-00295-4

Table 2.

Incidence and risk of incident IE

HR (95% CI) SHR(95% CI)
HTN level UW Participants, No. Event, No. Person-years, No. IR per 1000 PY Model 1a Model 2b Model 3c
Normal 374,586 168 2,596,618.93 0.0647 1 (Reference) 1 (Reference) 1 (Reference)
Pre-HTN 750,006 303 5,191,772.99 0.05836 0.903 (0.748-1.091) 0.909 (0.752-1.097) 0.918 (0.759- 1.109)
HTN 1,478,420 1,232 10,069,290.54 0.12235 1.892 (1.610-2.223) 1.343 (1.138-1.585) 1.360 (1.152-1.607)
HR (95% CI) SHR(95% CI)
Normal No 361,343 161 2,513,483·48 0.06405 1 (Reference) 1 (Reference) 1 (Reference)
Yes 13,243 7 83,135·44 0.0842 1.334 (0.626-2.843) 1.180 (0.554-2.517) 1.028 (0.482-2.194)
Pre-HTN No 737,610 295 5,115,472·1 0.05767 0.902 (0.744-1.093) 0.906 (0.747-1.098) 0.913 (0.753-1.107)
Yes 12,396 8 76,300·89 0.10485 1.663 (0.818-3.383) 1.387 (0.681-2.825) 1.209 (0.593-2.465)
HTN No 1,462,441 1210 9981453.39 0.12122 1.894 (1.607-2.232) 1.344 (1.135-1.590) 1.357 (1.145-1.609)
Yes 15,979 22 87,837·15 0.52046 4.012 (2.570-6.264) 2.221 (1.418-3.481) 1.748 (1.108-2.755)

a Model 1 was unadjusted

b Model 2 was adjusted for age, sex, lower income (lowest Q1), smoking, drinking, regular exercise, diabetes duration, chronic kidney disease, dyslipidemia, insulin use and oral hypoglycemic agents (≥3 types)

c Model 3 was adjusted for age, sex, lower income (lowest Q1), smoking, drinking, regular exercise, diabetes duration, chronic kidney disease, dyslipidemia, insulin use and oral hypoglycemic agents (≥3 types), considering death as a competing event

CI, confidence interval; HR, hazard ratio; HTN, hypertension; IR, incidence rate; IE, infective endocarditis; SHR, subdistribution hazard ratio; UW, underweight